Evidence map›Paper›PMID 37945035›Full record

ArticleThe European respiratory journal2023

Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.

Jay Achar, James A Seddon, Gwenan M Knight, Peter J Dodd, Hanif Esmail, Jennifer Hughes, C Finn McQuaid

Open access · greenAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Jay AcharDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden jay.achar@ki.se.ORCID 0000-0002-2521-4422
James A SeddonDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Gwenan M KnightTB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases and AMR Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0002-7263-9896
Peter J DoddSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Hanif EsmailMRC Clinical Trials Unit, University College London, London, UK.ORCID 0000-0002-4278-9316
Jennifer HughesDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
C Finn McQuaidTB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases and AMR Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-6199-0931
Desmond Tutu HIV Foundation · ZALondon School of Hygiene & Tropical Medicine · GBKarolinska Institutet · SEUniversity of Cape Town · ZAUniversity of Sheffield · GB

Funding

Medical Research Council MC_UU_00004/04Medical Research Council MR/R007942/1Medical Research Council MR/W029227/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDrug Resistance, BacterialHumansIsoniazidMicrobial Sensitivity TestsRifampinAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID37945035
OpenAlexW4388524164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.